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Purpose: Results for implantation efficiency and effective improvement of cardiac function in 
the field of mesenchymal stem cells (MSCs) are controversial. To attempt to clarify this debate, 
we utilized magnetic resonance imaging (MRI) and near-infrared optical imaging (OI) to explore 
the effects of different delivery modes of mesenchymal stem cells on cell retention time and 
cardiac function after myocardial infarction (MI).
Methods: Rat MSCs were labeled with superparamagnetic iron oxide nanoparticles and 1, 
1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) 
for noninvasive cell tracking in a rat MI model. Rats underwent coronary artery ligation and 
were randomized into three experimental groups: intravenous (IV), intramyocardial (IM), and 
a control group. The first two groups referred to the route of delivery of the transplanted dual-
labeled MSCs; whereas the control group was given an IV injection of serum-free medium 
one day post-MI. Cellular engraftment was determined 1 day and 7 days post cell delivery by 
measuring the iron and optical signals in explanted organs. Prussian blue staining and fluorescent 
microscopy were performed on histological sections for iron and DiD, respectively. Cardiac 
function was measured by echocardiography on day 7.
Results: The cardiac function of the IM group increased significantly compared to the IV and 
control groups at day 7. In the IM group, labeled cells were visualized in the infracted heart by 
serial MRI, and the intensity by OI was significantly higher on day 1. In the IV group, the heart 
signals were significantly attenuated by dual-modal tracking at two time points, but the lung 
signals in OI were significantly stronger than the IM group at both time points.
Conclusion: IM injection of MSCs increased cell engraftment within infarcted hearts and 
improved cardiac function after MI. However, IV infusion has a low efficacy due to the cell 
trapping in the lung. Therefore, direct injection may provide an advantage over IV , with regard 
to retention of stem cells and protection of cardiac function.
Keywords: stem cell tracking, superparamagnetic iron oxide, DiD, cardiac function, myocar-
dial infarction
Introduction
Myocardial infarction (MI) is one of the leading causes of death worldwide with an 
increasing morbidity and mortality of heart failure after MI.1 A loss of functional 
cardiomyocytes comprises the cellular basis for cardiac dysfunction and heart failure. 
Stem cell-based repletion of scarred myocardial tissue and regeneration of functional 
cardiomyocytes have been proposed as a potential treatment for the infarcted heart.2 
A number of major clinical trials have reported beneficial results, including improved 
cardiac contractile function and suppression of left ventricle remodelling.3 However, 
some researchers have shown only modest, negative, or merely a transient effect on International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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cardiac function.4–7 This indicates that factors such as cell 
type, number of transplanted cells, optimal timing, cell 
delivery route, and the mechanism of action remain to be 
explored.
Bone marrow-derived mesenchymal stem cells (MSCs) 
have the multipotent capability to differentiate under appro-
priate conditions into chondrocytes, tenocytes, myocytes, 
neurons, cardiomyocyte-like cells, vascular smooth muscle 
cells, and endothelial cells. Together this points to a high 
degree of plasticity,8,9 which has been used successfully in 
cell transplantation without immune rejection.10 There are, 
however, controversial results regarding implantation effi-
ciency and improved function in cardiac cell therapy.3,7,11,12 
These discrepancies may arise from the different modes 
of cell delivery. The appropriate delivery approach for 
MSC treatment post-MI has not been clarified. Intravenous 
infusion and intramyocardial injection are the current pre-
dominant stem cell delivery routes for the infarcted heart 
of small animals.13,14 Cell delivery by intravenous infusion 
has the advantage of simple administration, but Carr et al 
reported it could not ameliorate cardiac dysfunction.15 In 
contrast, the intramyocardial route has the associated disad-
vantages of being a highly invasive operation and requires 
a limited dose.16,17
Magnetic resonance imaging (MRI) possesses high 
spatial resolution, but less sensitivity in stem cell tracking. 
However, near-infrared (NIR) optical imaging (OI) has 
proven highly sensitive for in vivo cell tracking. We took 
advantage of these two imaging modalities for in vivo 
tracking of transplanted MSCs. This study was designed 
to compare the efficiency of MSC therapy through two 
delivery routes using MR and NIR optical dual-modality 
imaging techniques to determine the appropriate route of 
cell delivery for clinical use.
Materials and methods
experimental reagents
The following reagents were used in this study: fetal 
bovine serum (FBS; Gibco, Carlsbad, CA), Dulbecco’s 
modified Eagle’s medium (DMEM; Hyclone, Logan, UT), 
trypsin (Beyotime, Beijing, China), superparamagnetic 
iron oxide (SPIO; Feridex, Resovist, Berlin, Germany), 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 
4-chlorobenzenesulfonate salt (DiD; Invitrogen, Carlsbad, 
CA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT; Sigma, St Louis, MO), dimethyl sulfoxide 
(DMSO; Sigma), Prussian blue staining kit (Sigma), ED-1 
antibody (Abbiotec, San Diego, CA).
Msc culture and labeling
Male Sprague Dawley (SD) rat femurs and tibias were isolated 
under sterile conditions and bone marrow was flushed out 
using DMEM medium.18 Subsequently, single-nucleated cells 
were culture-expanded for three passages in vitro. Magnetic 
labeling of the MSCs was achieved by 24-hour incubation 
in culture medium containing a ferumoxides injectable 
solution (25 µg Fe per mL) mixed with poly-l-lysine (PLL; 
37.5 ng/mL; average molecular weight 275 kDa) 1 hour before 
cell incubation.19 After SPIO labeling, cells were trypsinized 
and then resuspended at a concentration of 1 × 106 cells/mL in 
serum-free DMEM medium. Sterile DiD cell-labeling stock 
solution was added to the cell suspension (5 µL per mL) fol-
lowed by incubation for 20 minutes at 37°C. After labeling, 
cells were washed three times with warm medium (37°C) to 
remove unbound DiD. Subsequently, the labeled cells were 
assessed by cell proliferation assay and labeling efficiency 
measurements or prepared for cell transplantation.
cell proliferation test
MTT assays were performed to monitor cell proliferation in 
the labeled and unlabeled cells. The labeled and unlabeled 
cells were seeded into 96 flat-bottom well plates with 2 × 103 
or 1 × 103 cells per well for measurements on day 3 or day 
7 post-seeding, respectively. After 3 or 7 days cultured in 
complete medium, 20 µL MTT solution (5 mg/mL) was 
added to each well and incubated for 4 hours at 37°C. The 
medium was removed and 150 µL DMSO added to each well, 
and quantified by measuring the optical density (OD) at a 
wavelength of 490 nm with the Bio-Rad microplate reader 
(Bio-Rad Laboratories, Hercules, CA).
Myocardial infarction model  
and cell transplantation
All animal studies were approved by the Institutional Animal 
Care and Use Committee of Southeast University. The recipi-
ent female SD rats (weight 80–100 g) were anesthetized with 
pentobarbital (30 mg/kg given intraperitoneally), intubated 
and ventilated at 60 breaths per minute. The left anterior 
descending coronary (LAD) artery was ligated proximally 
with 8–0 silk suture via a left thoracotomy incision.   Thirty-six 
rats with a left ventricular ejection fraction (LVEF) below 
40% as measured by echocardiography were used in this 
study. Rats were evenly randomized into control group, 
intravenous (IV) infusion group and intramyocardial (IM) 
injection group. Each rat among cell transplantation groups 
(IV or IM) received 1 × 106 dual-labeled MSCs in 100 µL 
of serum-free medium 1 day after operation by IV or direct International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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IM injection. In the control group, rats received the 100 µL 
of serum-free medium through an IV injection. Each of the 
three groups was divided evenly into two observation sub-
groups for 1 and 7 days post cell delivery.
cardiac function by echocardiography
All animals in Day 7 groups received cardiac function evalu-
ation by transthoracic echocardiography prior to sacrifice 
(Vevo 770TM; Visual Sonic, Toronto, Canada) as described 
  previously.20 Rats were anesthetized by isoflurane inhalation 
(1.5%), with heart rate maintained at ∼400 beats per minute 
and body temperature maintained at 37°C by placing rats on a 
heating pad. Left parasternal two-dimensional M-mode images 
under short-axis at the level of papillary muscles were recorded 
by using a 35-MHz linear transducer. Left ventricular end-
diastolic volume (LVEDV), left ventricular end-systolic volume 
(LVESV), left ventricular end-diastolic diameter (LVEDD) and 
left ventricular end-systolic diameter (LVESD) were measured. 
LVEF and left ventricular fractional shortening (LVFS) were 
calculated with standard M-mode echocardiographic equations 
(EF = LVEDV - LVESV/LVEDV × 100; FS = LVEDD - 
LVESD/LVEDD × 100). All measurements were averaged for 
five consecutive cardiac cycles and performed by an experienced 
examiner in a blinded fashion.
Mscs tracking by MrI
Cardiac MRI was performed 1 and 7 days post-cell deliveries. 
MR images were obtained with a conventional cardiac-gated 
fast low-angle shot (FLASH) sequence on a Bruker 7.0T 
magnetic resonance scanner (Bruker, Madison, WI). Rats 
were anesthetized with 1.5% isoflurane (KeYuan, Shandong, 
China) in 1 L/minute of oxygen and monitored using a small 
animal instrument monitoring and gating system for respira-
tion rate and electrocardiogram triggering. The field of view 
was 6 × 6 cm and a 256 × 256 matrix was employed, yielding 
an in-plane resolution of 234 × 234 µm. The images were 
acquired from successive slices along the short cardiac axis 
with a slice thickness of 1 mm; 16 slices were captured from 
apex to base. The repetition time was 70 ms, echo time was 
2.5 ms, and flip angle was 60°. The entire imaging protocol 
was performed in approximately 15 minutes.
Optical imaging study (in vivo, ex vivo)
The optical imaging experiments were performed using a CRi 
Maestro in vivo molecular imaging system (CRi, Woburn, 
MA) which permits coverage in the red, far-red, and NIR 
spectral regions. Light and cube images were acquired for 
in vivo or ex vivo study, respectively. After anesthetization, 
animals were shaved on the forelimbs, neck, chest, and 
abdomen and placed in a supine position. In vivo imaging 
was performed for each animal 1 or 7 days post delivery, fol-
lowed immediately by ex vivo imaging of explanted organs 
(heart, lung, liver, spleen, and kidney). NIR fluorescent signal 
average intensities from explanted organs were quantified as 
counts per second per pixels by software from CRi Maestro. 
Parameters were set as follows: excitation wavelength cover-
age 595–800 nm, emission coverage 660–680 nm.
histological analysis
After optical detection, the explanted hearts and lungs were 
subjected to fast-frozen sectioning for fluorescence microscopy, 
Prussian blue, and ED-1staining. Paraffin sections of heart tis-
sue were prepared for Masson trichrome staining and assessed 
for infarct size, which was quantified as a percentage of the left 
ventricular transverse perimeter occupied by collagen.
Data analysis
SPSS software (v. 11.5; SPSS Inc., Chicago, IL) was used 
for data analysis. All data is expressed as mean ± standard 
deviation of the mean for each time point. Multiple group 
comparisons were performed by using one-way analysis of 
variance; the significance of differences between two groups 
was analyzed by the Student’s t-test. All tests were two-tailed 
and a P-value , 0.05 was considered significant.
Results
Morphological observations of cultured 
cells, efficiency of double labeling
Single-nucleated cells were expanded for two passages and 
cells were spindle-shaped uniformly. After 14 days in culture, 
cells became compact and uniformly aligned in bundles with 
robust proliferation (Figure 1A and B). An aliquot of dual-
labeled cells were examined by Prussian blue staining to 
demonstrate the presence of intracellular SPIO. Cytoplasmic 
blue particles were observed and the labeling efficiency was 
almost 100% (Figure 1C). All cells were labeled positive for 
DiD by fluorescence microscopy (Figure 1D).
effect of dual-labeling on Msc 
proliferation
Cell proliferation was measured by MTT assay for both 
dual-labeled and unlabeled cells. As shown in Figure 1E, 
the difference in OD values between the two cell groups was 
not statistically significant (P . 0.05) at two time points, 
indicating that the dual-labeling of cells does not impart 
adverse effects on cell proliferation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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correlation between cell number  
and Mr T2 relaxometry (ms) or 
fluorescence intensity (counts)
Dual-labeled cells resuspended in algal-gel were transferred 
into 96-well plates at different cell concentrations. A phan-
tom of 2 × 105 cells appeared black, whereas a phantom 
of 0.125 × 105 cells appeared gray. A strong correlation 
between the number of cells and T2 relaxometry in the 
MR images was observed (R2 = 0.9547; Figure 2A and B). 
Fluorescence counts correlated linearly with cell number 
(y = -0.002 + 0.02x; R2 = 0.9976; Figure 2C and D).
effect of Msc transplantation on cardiac 
function and infarct size after MI
In the clinical setting, the prevention of progressive 
heart dysfunction as a result of myocardial infarction is 
Effect of dual-labeling on MSCs proliferation by MTT assay
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Figure 1 The culture and the dual-labeling of Mscs. A) At passage 2, Mscs appeared uniformly spindle-shaped (×100). B) cells became compact and uniformly aligned 
in bundles at day 14 (×100). C) Prussian blue-stained cells contained cytoplasmic blue particles and SPIO-labeling efficiency was almost 100% (×100). D) DiD-labeled cells 
appear red under fluorescence microscopy (×100; excitation wavelength 595–800 nm, emission 660–680 nm). E) cell proliferation viability was measured by MTT assay for 
dual-labeled and unlabeled cells 
Note: *P . 0.05.
Abbreviations:  Mscs,  mesenchymal  stem  cells;  sPIO,  superparamagnetic  iron  oxide  nanoparticle;  DiD,  1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 
4-chlorobenzenesulfonate salt; MTT, methyl thiazolyl tetrazolium.
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Figure 2 In vitro correlations between Mr T2 relaxometry or NIR fluorescent signal and the number of cells. A) A phantom of 2 × 105 cells appeared black, whereas 
a phantom of 0.125 × 105 cells appeared gray in the Mr images. B) A strong correlation between the number of cells and T2 relaxometry was observed (r2 = 0.9547).   
C) Fluorescent images showed that signal intensity increased with the increasing cell number. Bars represent maximum radiance. D) Correlation plot showed fluorescence 
counts correlated linearly with cell number (y = -0.002 + 0.02 x; r2 = 0.9976).
Abbreviations: Mr, magnetic resonance; NIr, near-infrared.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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vs 0.006 ± 0.001; 0.014 ± 0.003 vs 0.005 ± 0.001, respec-
tively, P , 0.01) (Figure 5A–C).
Monitoring (tracking) implanted  
cells by MrI
In the IM group, labeled cells were visualized in the infarcted 
myocardium as hypointense areas by serial MRI studies. 
While signal size decreased from day 1 to day 7, no signal 
was observed in IV group (Figure 4A and B).
histological examination
Fast-frozen sections of the myocardium and the lung in cell 
transplantation groups were prepared for Prussian blue stain-
ing and fluorescent detection. Blue SPIO particles and NIR 
fluorescent signals were observed in the myocardial section of 
the IM group at both time points. In contrast, SPIO particles 
and fluorescent signals were found only in the lungs of the 
IV group. Interestingly, a mass of transplanted cells were 
entrapped in the pulmonary interstitium (Figure 6A and B). 
Neither blue particles nor fluorescent signals were detected   
in the myocardium from the IV group (data not shown). Prus-
sian blue and ED-1 immunohistochemical costaining of the 
myocardium from the IM group 7 days post transplantation 
showed a distribution of blue particles nearly consistent with 
ED-1 immunohistochemical bright field staining, indicating 
that most implanted stem cells were phagocytosed by mac-
rophages (Figure 6C).
Discussion
In the current study, we found that highly efficient dual-
labeling of MSCs does not have adverse effects on cell 
proliferation over the course of 1 week. Further, direct IM 
injection of MSCs could increase the cell engraftment and 
significantly improve ventricular contractility post MI.
There are controversial results regarding implantation 
efficiency and improved function in cardiac cell therapy. 
These discrepancies may arise from the different modes of 
Table 1 echO parameters of LV cardiac function and infarct 
size among three groups 7 days after cell delivery
Control (6) IV (6) IM (6)
LVEF (%) 36.68 ± 1.11 36.62 ± 1.18 41.45 ± 1.54*
LVFS (%) 18.02 ± 0.72 17.98 ± 0.71 20.51 ± 0.84*
Infarct size (%) 41.12 ± 3.3 40.92 ± 3.27 23.10 ± 1.98*
Notes: Data represented as mean ± sD. *P , 0.01, IM group compared with IV 
group and control group. Infarct size was quantified as a percentage of the LV 
transverse perimeter occupied by collagen.
Abbreviations: echO, echocardiography; LV, left ventricular; LVeF, left ventricular 
ejection fraction; Fs, fractional shortening; c, control group; IV, intravenous group; 
IM, intramyocardial group; sD, standard deviation.
A
CI VI M
IV IM C B
Figure 3 Measurements of cardiac function and infarct size. A) representative 
M-mode images at the level of papillary muscles were recorded among three groups. 
B)  representative  Masson’s  trichrome-stained  histological  sections  to  measure 
infarct size. collagen presented blue but myocardium appeared red. Infarct size was 
quantified as the area occupied by collagen (blue; yellow hash marks).
Abbreviations: c, control group; IV, intravenous group; IM, intramyocardial group.
of great importance. To this purpose, cardiac functional 
outcomes evaluated 1 week after cell delivery by echocar-
diography are shown in Figure 3A and Table 1. In the control 
and IV group, markedly decreased fractional shortening (FS) 
and ejection fraction (EF) compared with the IM group were 
observed (P , 0.01), corresponding to post-infarction myo-
cardial systolic failure. However, there were no significant 
differences between the control and IV groups (P . 0.05). 
One week after cell transplantation, infarct size was assessed 
by Masson trichrome staining in each experimental group 
and quantified as a percentage of the left ventricular trans-
verse perimeter occupied by collagen. While there were no 
differences between the control and IV group (P . 0.05), 
transplantation by IM was associated with a significant 
improvement in infarct size compared to the aforementioned 
two groups (P , 0.01; Figure 3B and Table 1).
Distribution of implanted cells  
assessed by OI
The in vivo NIR fluorescent signals of transplanted dual-
labeled MSCs on rat chests were evaluated in all groups by 
OI (Figure 4A and B). No fluorescent signals were observed 
in the area of the heart among control and IV groups at the 
two time points, but signals in IM groups last over 1 week. 
Quantitative analysis of the fluorescent signals in explanted 
hearts among two cell transplantation groups showed that 
the bulk of injected cells disappeared and only 2.3%–0.6% 
of cells survived from 1 to 7 days post cell delivery in the 
IV group (compared to the dose of transplanted cells), and 
approximately 23.8%–2.0% of transplanted cells survived 
in the IM group during the same time frame. The fluores-
cent signals of the lungs in the IV group were 5.8–2.8 fold 
higher than the IM group at two time points (0.037 ± 0.003 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cell delivery. To our knowledge, this is the first report of com-
bined MR and NIR optical imaging techniques to explore the 
efficacy of two cell delivery routes in a rat model of MI.
The development of molecular imaging techniques 
has allowed visualization of stem cell homing, migration, 
location, and proliferation.21 Although there are no current 
ideal imaging modalities for in vivo stem cell tracking, each 
individual imaging modality presents unique advantages and 
disadvantages. Thus, multimodality may provide a useful 
means for stem cell tracking.22 Imaging by high-field MR 
B
NIR optical imaging MR imaging
A
CI VI M
IM IV
IV IM
IM IV C
Figure 4 The in vivo NIR fluorescent signal and MR detections. No fluorescent signals were observed in the heart areas of control and IV groups at two time points, but the 
signals in IM groups lasted over 1 week. Mr imaging showed that sPIO-labeled cells were visualized in the infarcted myocardium as hypointense areas by serial MrI studies 
from day 1 to day 7 in the IM group, but no signals were found in the IV group. A) One day after cell delivery. B) seven days after cell delivery.
Abbreviations: NIr, near-infrared; Mr, magnetic resonance; sPIO, superparamagnetic iron oxide; c, control group; IV, intravenous group; IM, intramyocardial group.
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Figure 5 ex vivo optical imaging study. A–B) Representative NIR fluorescent images in explanted organs 1 or 7 days after labeled MSCs were implanted into rats by means 
of intravenous or intramyocardial delivery 1 day after coronary artery ligation. C) Quantitative analysis of NIR fluorescent signals in explanted hearts and lungs among the 
two cell transplanted groups, indicating that cell delivery by direct IM injection resulted in a 3–10-fold higher fluorescent signal than IV infusion in explanted hearts from day 
1 to day 7. In contrast, compared with the IM group, NIR fluorescent signals exist in lungs from the IV group during 1 week post cell delivery. (A: One day after cell delivery. 
B: seven days after cell delivery).
Abbreviations: NIr, near-infrared; h, heart; L, lung; c, control group; IV, intravenous group; IM, intramyocardial group.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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scanners enables us to study rodent cardiac structure and 
noninvasively track stem cells in an infarcted heart.23 Using 
a 7.0-Tesla scanner to identify transplanted cells by MR, we 
identified the IM injection sites of iron-labeled MSCs as dark 
spots in vivo. The signal size faded during 1-week follow-up, 
indicating that the transplanted cells were gradually lost in 
heart tissue. However, imaging by MR has low sensitivity and 
fails to quantify the number of engrafted cells.24 In parallel, 
using the proven highly sensitive optical imaging for in vitro 
cell labeling and in vivo cell tracking,25 we observed that 
MSCs could be labeled efficiently by DiD in vitro and fluo-
rescence counts correlated linearly with cell number increase, 
allowing cell engraftment to be assessed in explanted hearts. 
Ex vivo studies showed that more MSCs were engrafted into 
the myocardium in the IM group compared to the IV group. 
Conversely, a majority of cells were entrapped in the lungs of 
the IV group. These findings are in agreement with previous 
studies describing that very few stem cells homed to infarcted 
myocardium through IV infusion.26,27
IV infusion and IM injection are currently the predomi-
nant stem cell delivery routes for the injured heart of small 
animals. Each transplant route attempts to maximize not only 
the ease of administration, but the targeted homing, retention, 
stem cell engraftment to damaged myocardium and improved 
cardiac function.28 The therapeutic effect(s) of MSCs relies 
on their capacity to engraft and survive in distinctive target 
tissue, and poor stem cell survival is responsible for unsat-
isfactory cell transplantation prognosis post MI.29 Compared 
to IV infusion, cell delivery by IM injection increased the 
engraftment and survival of MSCs in infarcted hearts. These 
results might explain why cell delivery by the IM route could 
ameliorate the cardiac function and infarct size post MI, 
rather than by IV infusion.
The precise mechanisms of the beneficial effects of trans-
planted MSCs are uncertain. Our recent research suggested 
that the major mechanism of functional benefits appears to 
be paracrine pathways of the engrafted EPCs (endothelial 
progenitor cells) post MI, which facilitates endogenous repair 
processes.30 The targets of these paracrine effects most likely 
include both mature cells and resident progenitor cells in the 
recipient heart, which can induce neovascularization, inhibit 
apoptosis, reduce infarct size and scar formation, and improve 
myocardial contractility.31,32 Although costaining of iron and 
ED-1 in myocardium showed that most transplanted cells had 
Optical imaging Prussian blue staining
C
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B
Prussian blue stainingO ptical imaging
H/IM L/IV L/IV
L/IV L/IV H/IM
H/IM
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Figure 6 Cryosections of the myocardium and the lung were detected by Prussian blue staining, fluorescence microscopy, and immunohistochemical staining. A–B) sPIO 
blue particles and NIR fluorescent signals were observed in the myocardium of the IM group at two time points. However, in the IV group, SPIO particles and fluorescent 
signals were found only in the lungs. Interestingly, a mass of transplanted cells were located in pulmonary interstitium. (×100; A: One day after cell delivery, B: seven days after 
cell delivery). C) section from infarcted myocardium in the IM group at day 7 was determined by Prussian blue and eD-1 immunohistochemical costaining. The distribution 
of blue particles was consistent with eD-1staining, indicating that most implanted stem cells were phagocytosed by macrophages (×400).
Abbreviations: sPIO, superparamagnetic iron oxide; NIr, near-infrared; h, heart; L, lung; IV, intravenous group; IM, intramyocardial group.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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been phagocytosed by macrophages in the infarcted heart 
on day 7, the OI detection from cryosections and explanted 
hearts in the IM group indicated that some remaining 
implanted MSCs survived or may have differentiated into 
other cardiac cell lineages, as described by the most recent 
findings of Tsuji and colleagues describing transdifferentia-
tion of MSC application in the infarcted myocardium.33
The rats used in this study were low in weight, and a low 
dose of transplanted cells (1 × 106 per rat) was applied. We 
speculate that the administration of a higher dose of cells or 
genetically modified stem cells may produce better outcomes 
despite IV or IM delivery route. Regardless, these data indi-
cate that the optimal transplantation route likely plays an 
important role in cardiac cell therapy and the IM route may 
provide an advantage over IV infusion for retention of stem 
cells and cardiac function protection.
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